Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Glycoprotein 41 pipeline drugs market research report outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.

Glycoprotein 41 Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy area in the Glycoprotein 41 pipeline drugs market is infectious disease.

Glycoprotein 41 Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of action in the Glycoprotein 41 pipeline drugs market is Glycoprotein 41 Inhibitor.

Glycoprotein 41 Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Glycoprotein 41 pipeline drugs market are intramuscular, oral, subcutaneous, intravenous, nasal, parenteral, topical, and vaginal.

Glycoprotein 41 Pipeline Drugs Market Analysis, by Routes of Administration

Glycoprotein 41 Pipeline Drugs Market Analysis, by Routes of Administration

For more Glycoprotein 41 pipeline drugs routes of administration insights, download a free report sample

Glycoprotein 41 Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Glycoprotein 41 pipeline drugs market are synthetic peptide, monoclonal antibody, subunit vaccine, recombinant peptide, recombinant protein, recombinant vector vaccine, small molecule, and vaccine.

Glycoprotein 41 Pipeline Drugs Market Analysis, by Molecule Types

Glycoprotein 41 Pipeline Drugs Market Analysis, by Molecule Types

For more Glycoprotein 41 pipeline drugs molecule type insights, download a free report sample

Competitive Landscape

Some of the leading companies in the Glycoprotein 41 pipeline drugs market are Frontier Biotechnologies Inc, Longevity Biotech Inc, MacroGenics Inc, Minka Therapeutics SA, Molecular Express Inc, Mymetics Corp, Navigen Inc, Novodux, Osel Inc, and Protheragen Inc.

Glycoprotein 41 Pipeline Drugs Market Analysis, by Companies

Glycoprotein 41 Pipeline Drugs Market Analysis, by Companies

To know more about the Glycoprotein 41 pipeline drugs companies, download a free report sample

Glycoprotein 41 Pipeline Drugs Market Report Overview

Key Therapy Areas Infectious Disease
Key Mechanism of Actions Glycoprotein 41 Inhibitor
Key Routes of Administration Intramuscular, Oral, Subcutaneous, Intravenous, Nasal, Parenteral, Topical, and Vaginal
Key Molecule Types Synthetic Peptide, Monoclonal Antibody, Subunit Vaccine, Recombinant Peptide, Recombinant Protein, Recombinant Vector Vaccine, Small Molecule, and Vaccine
Leading Companies Frontier Biotechnologies Inc, Longevity Biotech Inc, MacroGenics Inc, Minka Therapeutics SA, Molecular Express Inc, Mymetics Corp, Navigen Inc, Novodux, Osel Inc, and Protheragen Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41).
  • Reviews of Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects.
  • Assessment of Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Frontier Biotechnologies Inc
Longevity Biotech Inc
MacroGenics Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
Navigen Inc
Novodux
Osel Inc
Protheragen Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glycoprotein 41 (gp41) – Overview

Glycoprotein 41 (gp41) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycoprotein 41 (gp41) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycoprotein 41 (gp41) – Companies Involved in Therapeutics Development

Frontier Biotechnologies Inc

Longevity Biotech Inc

MacroGenics Inc

Minka Therapeutics SA

Molecular Express Inc

Mymetics Corp

Navigen Inc

Novodux

Osel Inc

Protheragen Inc

Glycoprotein 41 (gp41) – Drug Profiles

albuvirtide LA – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cl3hmAb – Drug Profile

Product Description

Mechanism Of Action

History of Events

CPT-31 – Drug Profile

Product Description

Mechanism Of Action

History of Events

DS-007 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HIV-1 vaccine – Drug Profile

Product Description

Mechanism Of Action

human immunodeficiency virus (virus like particles) vaccine – Drug Profile

Product Description

Mechanism Of Action

LBT-5001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MGD-020 – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Target GP120 and GP41 for HIV – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Target GP41 for HIV Infections – Drug Profile

Product Description

Mechanism Of Action

History of Events

MPER-656 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MYMV-101 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Peptides to Inhibit gp41 for HIV-1 Infection – Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhbit GP41 for HIV Infections – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection – Drug Profile

Product Description

Mechanism Of Action

VAC-02 – Drug Profile

Product Description

Mechanism Of Action

VAC-3S – Drug Profile

Product Description

Mechanism Of Action

History of Events

Glycoprotein 41 (gp41) – Dormant Products

Glycoprotein 41 (gp41) – Discontinued Products

Glycoprotein 41 (gp41) – Product Development Milestones

Featured News & Press Releases

Dec 27, 2021: Frontier Bio’s “Spring Breeze Program” is dedicated to the treatment of AIDS patients in low-income areas

Nov 26, 2021: “China AIDS Diagnosis and Treatment Guidelines (2021 Edition)” introduces Aikening as a recommended treatment plan for post-exposure prevention of AIDS

Oct 27, 2021: Frontier Biotechnologies long-acting injectable (Aikening(R)), in a two drug regimen, proves safe and effective for critically ill hospitalized AIDS patients

Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients

Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor

Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study

Aug 21, 2018: Frontier Biotech’s novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China’s first new drug for the treatment of HIV

Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31

Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science

Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Frontier Biotechnologies Inc, 2022

Pipeline by Longevity Biotech Inc, 2022

Pipeline by MacroGenics Inc, 2022

Pipeline by Minka Therapeutics SA, 2022

Pipeline by Molecular Express Inc, 2022

Pipeline by Mymetics Corp, 2022

Pipeline by Navigen Inc, 2022

Pipeline by Novodux, 2022

Pipeline by Osel Inc, 2022

Pipeline by Protheragen Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.